Navigation Links
New tuberculosis drug trial begins in South Africa
Date:12/11/2012

Case Western Reserve University School of Medicine and AstraZeneca, a global biopharmaceutical company, today announced the first patient enrolled in a Phase 2a trial to assess the effectiveness of AZD5847, a new test drug for patients with tuberculosis (TB), including patients with HIV co-infection.

The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health. It is being conducted by the NIAID-supported Tuberculosis Research Unit of Case Western University School of Medicine of Cleveland, Ohio, and is taking place in Cape Town, South Africa with TASK Applied Science, a South African clinical research group that specializes in TB trials.

TB, which causes 1.4 million deaths per year, is the leading infectious cause of death among people with HIV/AIDS . The emergence of drug-resistant TB and the lack of new drugs to fight the disease effectively are major challenges to controlling this serious global public health concern.

"New medications are greatly needed to improve and shorten the treatment of TB in high-burden countries," says John L. Johnson, MD, professor of medicine in the Division of Infectious Diseases and HIV Medicine at Case Western Reserve School of Medicine and staff physician at University Hospitals Case Medicine Center. "This trial is the first step in testing this new potential drug in humans with active TB."

Johnson is an internationally-renowned investigator with the Tuberculosis Research Unit at Case Western Reserve, an inter-disciplinary, inter-national consortium of investigators and institutions with expertise in epidemiology, microbiology, immunity, prevention and treatment of TB. Supported by the NIH, the Tuberculosis Research Unit is the only NIH-funded research unit in the US focused on human TB.

AZD5847 has been developed by AstraZeneca and belongs to a class of antibiotics that are active against Gram-positi
'/>"/>

Contact: Jessica Studeny
jessica.studeny@case.edu
216-368-4692
Case Western Reserve University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Biosignatures distinguish between tuberculosis and sarcoidosis
2. Targeting tuberculosis hotspots could have widespread benefit
3. MIT-designed cooler preserves tuberculosis drugs, records doses
4. Research on improvements in diagnosing and treating tuberculosis
5. Millions of diabetics could die of tuberculosis
6. New approach of resistant tuberculosis
7. Iowa State, Ames Lab researchers study the structure of drug resistance in tuberculosis
8. High doses of Vitamin D help tuberculosis patients recover more quickly
9. Scientists reveal how natural antibiotic kills tuberculosis bacterium
10. Notre Dame research could provide new insights into tuberculosis and other diseases
11. Missing link discovered in the defence mechanism of the tuberculosis pathogen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2015)... , Feb. 12, 2015   MedNet Solutions ... in clinical study management systems, has recently bolstered ... further distinguishing iMedNet as ... Organizations (CROs) and healthcare consultants.  Building on the ... customer referrals and numerous co-marketing opportunities), MedNet,s new ...
(Date:2/9/2015)... Texas , Feb. 9, 2015  Lintec of ... fabrication methods for carbon nanotube (CNT) macrostructures, including sheets, ... at Dallas (UTD). Leveraging the vast industrial ... Tokyo, Japan , Lintec of America is ... Richardson, TX , focusing on scaling up ...
(Date:2/5/2015)... Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... ( http://www.nxt-id.com/ ) as part of its 2015 marketing ... Company launched its new consumer website for Wocketwallet.com earlier ... CEO of NXT-ID said, "Our new corporate website naturally ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... researchers are developing two inexpensive technologies that may be ... recent outbreak of E. coli in contaminated spinach. , ... , The first method uses a laser to ... about three times faster and one-tenth as expensive as ...
... how much detail one remembers of an event depends on ... "package" the memory. , The research may help to explain ... as a car accident, and yet vividly recall all of ... using functional magnetic resonance imaging (fMRI), the scientists were able ...
... (UC) environmental health researchers have determined that firefighters are ... cancer than workers in other fields. , Their findings ... the past didn't do a good job in protecting ... the researchers say. , The researchers found, for ...
Cached Biology News:Researchers develop technologies to devour food pathogens 2Researchers develop technologies to devour food pathogens 3Memories: It's all in the packaging, scientists say 2Firefighters face increased risk for certain cancers 2
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/nqxxt3/biomarkers ... new report "Biomarkers - Technologies, Markets and ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:3/4/2015)... CA (PRWEB) March 04, 2015 ... leader in Personalized Medicine, is excited to announce ... Genetic Testing to Optimize the Management of Pain”. ... available at Medscape.com for the next year. The ... professionals how to recognize inadequate pain treatments, integrate ...
(Date:3/4/2015)... Follow us on LinkedIn - ... growing technologies in the life sciences industry. Growing global ... growth in nucleic acid detection technologies like qPCR and ... will continue to benefit the qPCR and dPCR instruments ... pharma, biotech, food & beverage to animal feed, will ...
(Date:3/3/2015)... and TORONTO, March 3, 2015 /PRNewswire/ - Aptose Biosciences ... new therapeutics and molecular diagnostics that target the underlying ... quarter and seventh-month period ended December 31, 2014. ... fiscal year end from May 31 to December 31. ... are reporting today are for the quarter and the ...
Breaking Biology Technology:Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... SHANGHAI, July 15 /PRNewswire-Asia-FirstCall/ -- ... a leading Chinese firm,specializing in the manufacture, research, development, ... results for,the fourth quarter and fiscal year ended March ... 2009 Highlights, -- Net sales increased ...
... Mass., July 14 The Huffington Post -- ,The ... with astronomer Bob Berman) " Biocentrism." The article by ... universe. The Huffington Post is ranked the most powerful ... over 20 million thought-leaders, and has featured celebrity contributors from politics ...
... EnVivo Pharmaceuticals today announced at the Alzheimer,s Association 2009 ... deficits observed in an Alzheimer,s disease transgenic animal model after ... data was disclosed as part of the preclinical characterization of ... , EVP-0962 is a proprietary small molecule that ...
Cached Biology Technology:China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 2China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 3China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 4China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 5China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 6China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 7China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 8China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 9China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 10China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 11China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 12China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13New Scientific Worldview 'Biocentrism' Featured in The Huffington Post - #1 Weblog in the World 2EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer's Disease Transgenic Mouse Model With Gamma-Secretase Modulator 2
...
Luminometers...
... Designed for serial preparation ... fractions including cytosol/particulate/cytoskeleton/nuclear fractions ... these fractions can directly ... assays such as 2-D ...
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
Biology Products: